According to the brand's published documentation, the arginate salt offers greater stability in the gastrointestinal environment compared to acetate, and this was the deliberate formulation choice made to support consistency and potency in capsule delivery.* That rationale is stated by the brand and reflected on the product page
The SFN extract was found to be highly effective in blocking the activity of inactivation of an oncogenic factor pSTAT3
[9] [10] FDA warnings include risks of pancreatitis and gallbladder disease
Anti-LC3B (D11), anti-GAPDH antibodies, and senescence -galactosidase staining kit were purchased from Cell Signaling Technology (Danvers, MA, USA)
Researchers also associate ending GLP-1 therapy before pregnancy with a few risks.* Women who stopped taking a GLP-1 RA before or during early pregnancy had roughly 1.3x the risk of preterm birth, gestational diabetes, and high blood pressure conditions during pregnancy, compared to similar women who had not taken a GLP-1 RA
Am J Med 2019